Stockscreener 앱 받기
3.28
0.61%
0.02
Jupiter Neurosciences Inc 주식(JUNS)의 최신 뉴스
Jupiter Neurosciences, Inc. stock plunges 44% after spiking to $11.14 - Cryptonews.net
Jupiter Neurosciences, Inc. stock Analysis: August 2026 Volatility & Trend Review - The Cryptonomist
Best Pharmaceutical Stocks To Watch TodayAugust 21st - MarketBeat
Friday's session: most active stocks - ChartMill
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Jupiter Neurosciences Prices $2.0 Million Direct Offering - marketscreener.com
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - The Manila Times
Jupiter Neurosciences proposes selling 307,692 shares for about $2 million - Stock Titan
Jupiter Neurosciences Jumps 59% as Volume Hits 59 Times Its Share Count - TechStock²
Jupiter Neurosciences Surges as Post-Split Float Shrinks and Traders Revisit Pipeline Expansion - Quiver Quantitative
JUNS Stock Whipsaws As New Insider Ownership Is Disclosed - timothysykes.com
JUNS Stock Draws Focus After New Insider Ownership Filing - StocksToTrade
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action? - Benzinga
JUNS Stock Jumps As New Insider Ownership Revealed - StocksToTrade
JUNS Stock Jumps As New Insider Ownership Comes To Light - timothysykes.com
Which stocks are moving before the opening bell on Friday? - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
JUNS Stock Whipsaws As New Insider Files Form 3 - StocksToTrade
Jupiter (JUNS) Trading: Posts a 3.81% Loss to $4.80 on the Day; Immediate View: the $4.56 to $5.04 Range Remains in Focus in the Current UpdateEase of Movement - vinanet.vn
Andrew Jon Cutler Net Worth (2026) - GuruFocus
Real Parkinson’s Disease Hope from Jupiter Neurosciences - Yahoo Finance
Jupiter Neurosciences, Inc. Common Stock (NASDAQ: JUNS) Stock Price, News & Analysis - Kalkine
Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current UpdateDebt Analysis Report - Vinanet
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Meets 6.16% Surprise but Shares Slide 12.67%Dividend Earnings Report - Vinanet
JUNS Q4 2025 Earnings: Narrower Loss Beats Estimates; Shares Slide 12.67%EPS Surprise History - vinanet.vn
JUNS Q4 2025 Earnings: Smaller Loss per Share Beats Estimate, But Shares Slip 12.67%Earnings Call Highlights - Vinanet
Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jupiter Neurosciences Stock Short Interest Falls to 34.91% - Quiver Quantitative
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
JUNS|Jupiter Neurosciences Inc|Price:5.100|Chg%:-0.533 - TradingKey
Market Movers | Winners: ATTO, JUNS, XHLD | Losers: TDUP, BLLN, UWMC - Trefis
Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Jupiter Neurosciences Enacts 1-for-75 Reverse Stock Split - TipRanks
Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com - Investing.com UK
Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading - Stock Titan
Jupiter Neurosciences executes 1-for-75 reverse stock split - Investing.com
Jupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026 - Quiver Quantitative
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewswire
Kaskela Law Firm Announces Stockholder Investigation of Jupiter N - The National Law Review
Jupiter Neurosciences expands into psychedelics with $100m deal - Longevity.Technology
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Beats Estimates as Pre-Revenue Biotech Maintains Pipeline FocusTax Rate Impact - vinanet.vn
Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA - Stock Titan
Jupiter Neurosciences Inc (JUNS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jupiter Neurosciences Stockholders Approve Key 2026 Actions - TipRanks
Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status - Minichart
Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms - Stock Titan
Jupiter Neurosciences Inc (JUNS) Cash Flow - TradingKey
Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jupiter Neurosciences Inc (JUNS) Balance Sheet - TradingKey
Jupiter Neurosciences, Inc. Revenue Breakdown – NASDAQ:JUNS - TradingView
Jupiter Neurosciences (JUNS) Plunges Over 20% as Selling Pressure IntensifiesPut Wall - Vinanet
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout | AI
Jupiter Neurosciences Inc (JUNS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jupiter Neurosciences Secures Exclusive U.S. Rights to MDMA Formulation in PharmAla Licensing DealEarnings Power Value - vinanet.vn
Jupiter Neurosciences Expands CNS Pipeline with $100M ALA-002 Licensing DealEPS Surprise History - dars.gov.et
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences - TipRanks
Jupiter Neurosciences licenses MDMA drug in deal worth up to $100M - Dealroom
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionProfit Cycle Analysis - Vinanet
Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statement - Bitget
0.86%
0.31%
자본화:
|
볼륨(24시간):